EUVIMEDEUVIMED entdecken
Crossref

Face validation and pharmacologic analysis of Sik3 mutant mouse as a possible model of idiopathic hypersomnia

Asmaa Elhosainy, Haruka Suzuki-Abe, Mahesh K Kaushik, Staci J Kim, Tsuyoshi Saitoh, Yukiko Ishikawa, Noriko Hotta-Hirashima, Chika Miyoshi, Hiromasa Funato, Masashi Yanagisawa

European Journal of Pharmacology · 2023

DOI: 10.1016/j.ejphar.2023.175877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2023. Verfasst von Asmaa Elhosainy und 9 weiteren Autor:innen. Beteiligte Einrichtung: International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Idiopathic Hypersomnia, Disorders of Excessive Somnolence. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, CREST, Core Research for Evolutional Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic hypersomnia (IH) is a chronic neurologic disorder with unknown mechanisms that result in long night-time sleep, daytime sleepiness, long non-refreshing naps, and difficult awakening presenting as sleep drunkenness. IH patients are typically diagnosed by shorter sleep latency on multiple sleep latency test (MSLT) along with long sleep time. Only symptomatic drug treatments are currently available for IH and no animal model to study it. Sleepy mice carry a splicing mutation in the Sik3 gene, leading to increased sleep time and sleep need. Here we used a mouse version of MSLT and a decay analysis of wake EEG delta power to validate the Sleepy mutant mouse as an animal model for IH. Sleepy mice had shorter sleep latency in the dark (active) phase than wild-type mice. They also showed lower decay of EEG delta density during wakefulness, possibly reflecting increased sleep inertia. These data indicate that the Sleepy mouse may have partial face validity as a mouse model for idiopathic hypersomnia. We then investigated the effect of orexin-A and the orexin receptor 2-selective agonist YNT-185 on the sleepiness symptoms of the Sleepy mouse. Intracerebroventricular orexin-A promoted wakefulness for 3 h and decreased wake EEG delta density after injection in Sleepy mice and wild-type mice. Moreover, Sleepy mice but not wild-type mice showed a sleep rebound after the orexin-A-induced wakefulness. Intraperitoneal YNT-185 promoted wakefulness for 3 h after injection in Sleepy mice, indicating the potential of using orexin agonists to treat not only orexin deficiency but hypersomnolence of various etiologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic HypersomniaDisorders of Excessive SomnolenceMiceAnimalsOrexinsWakefulnessSleepinessSleepAniline CompoundsBenzamides

Stichwörter der Autor:innen

Idiopathic hypersomniaOrexinOrexin agonistSleep inertiaSleepy mouse

Substanzen

OrexinsYNT-185Aniline CompoundsBenzamides

Autor:innen und Institutionen

  • International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan; Department of Anatomy, Graduate School of Medicine, Toho University, Tokyo, Japan.
  • International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan; Life Science Centre for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Ts…

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • CREST
  • Core Research for Evolutional Science and Technology
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Elhosainy, A., Suzuki-Abe, H., Kaushik, M. K., Kim, S. J., Saitoh, T., Ishikawa, Y., Hotta-Hirashima, N., Miyoshi, C., Funato, H., & Yanagisawa, M. (2023). Face validation and pharmacologic analysis of Sik3 mutant mouse as a possible model of idiopathic hypersomnia. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2023.175877

Vancouver

Elhosainy A, Suzuki-Abe H, Kaushik MK, Kim SJ, Saitoh T, Ishikawa Y, et al. Face validation and pharmacologic analysis of Sik3 mutant mouse as a possible model of idiopathic hypersomnia. European Journal of Pharmacology. 2023. doi:10.1016/j.ejphar.2023.175877

BibTeX
@article{Elhosainy2023,
  author = {Elhosainy, Asmaa and Suzuki-Abe, Haruka and Kaushik, Mahesh K and Kim, Staci J and Saitoh, Tsuyoshi and Ishikawa, Yukiko and Hotta-Hirashima, Noriko and Miyoshi, Chika and Funato, Hiromasa and Yanagisawa, Masashi},
  title = {Face validation and pharmacologic analysis of Sik3 mutant mouse as a possible model of idiopathic hypersomnia},
  journal = {European Journal of Pharmacology},
  year = {2023},
  doi = {10.1016/j.ejphar.2023.175877}
}
Kostenlos starten →